
(IN BRIEF) Research presented at ESC Congress 2025 has shown that GLP-1 receptor agonists, used to treat patients with heart failure and preserved ejection fraction, not only reduce hospitalizations and improve outcomes but also cut the environmental footprint of healthcare. … Read the full press release